-
公开(公告)号：US20130338084A1
公开(公告)日：2013-12-19
申请号：US13863294
申请日：2013-04-15
摘要： Hydrogel compositions comprise an aqueous dispersion phase and a plurality of peptides, or derivatives, or analogues thereof. Each peptide comprises at least two amino acid residues and an aromatic stacking ligand and the hydrogel is formed by self-assembly of said peptides in said aqueous dispersion medium. The aqueous dispersion phase is physiologically acceptable and may have a pH of 6 to 8, as may the hydrogel itself. The hydrogel may be used for cell culture or for treatment of medical conditions characterised by tissue loss/damage.
摘要翻译： 水凝胶组合物包含水性分散相和多种肽或其衍生物或类似物。 每个肽包含至少两个氨基酸残基和芳族叠层配体，并且通过所述肽在所述水性分散介质中的自组装形成所述水凝胶。 水分散相在生理上是可接受的，并且可以具有6至8的pH，如水凝胶本身。 水凝胶可用于细胞培养或用于治疗以组织损失/损伤为特征的医学病症。
-
公开(公告)号：US08420605B2
公开(公告)日：2013-04-16
申请号：US11470962
申请日：2006-09-07
摘要： Hydrogel compositions comprise an aqueous dispersion phase and a plurality of peptides, or derivatives, or analogues thereof. Each peptide comprises at least two amino acid residues and an aromatic stacking ligand and the hydrogel is formed by self-assembly of said peptides in said aqueous dispersion medium. The aqueous dispersion phase is physiologically acceptable and may have a pH of 6 to 8, as may the hydrogel itself. The hydrogel may be used for cell culture or for treatment of medical conditions characterized by tissue loss/damage.
摘要翻译： 水凝胶组合物包含水性分散相和多种肽或其衍生物或类似物。 每个肽包含至少两个氨基酸残基和芳族叠层配体，并且通过所述肽在所述水性分散介质中的自组装形成所述水凝胶。 水分散相在生理上是可接受的，并且可以具有6至8的pH，如水凝胶本身。 水凝胶可用于细胞培养或用于治疗以组织损失/损伤为特征的医学病症。
-
公开(公告)号：US12044639B2
公开(公告)日：2024-07-23
申请号：US17627401
申请日：2020-07-17
CPC分类号： G01N24/006 , G01R33/26
摘要： An atomic magnetometer system is disclosed that includes a variable magnetic field source (14) configured to provide an oscillating primary magnetic field to cause a sample (16) to produce a secondary magnetic field. The atomic magnetometer system also includes an atomic magnetometer for detecting the secondary magnetic field. The atomic magnetometer includes an atomic specimen, a pump and probe subsystem configured to pump the atomic specimen to create a polarisation and to probe atomic coherence precession within the atomic specimen with a probe beam, a detector configured to detect the probe beam to produce a detection signal. The system is configured to drive the variable magnetic field source (14) in dependence on the detection signal with a frequency tuned to rf resonance. A method of operating an atomic magnetometer is also disclosed.
-
公开(公告)号：US20240085501A1
公开(公告)日：2024-03-14
申请号：US17766926
申请日：2020-10-06
IPC分类号： G01R33/26
CPC分类号： G01R33/26
摘要： Disclosed is a method of generating atomic spin orientation in an atomic ensemble. The method includes providing a steady magnetic field (5) to the atomic ensemble to cause a Zeeman splitting within first and second manifolds of the ground state of the atomic energy levels of the atomic ensemble. The method includes pumping the atomic ensemble with an electromagnetic optical radiation beam, the beam being detuned from a transition involving the first manifold such that a majority of the atomic population of the first manifold in the atomic ensemble is transferred from the first manifold into a magnetic Zeeman sublevel of the second manifold. A system for generating an atomic spin orientation in a 15 atomic ensemble is also disclosed.
-
5.发明授权公开(公告)号：US11524080B2
公开(公告)日：2022-12-13
申请号：US17273059
申请日：2019-09-13
IPC分类号： A61K47/69 , A61K47/54 , A61P31/14 , A61P31/04 , A61K9/127 , A61K31/496 , A61K31/513 , A61K31/5383 , A61K31/65 , A61K31/711 , A61K38/21 , A61K47/14 , A61K47/24 , A61K47/26 , A61K47/28 , A61K47/42 , C07K16/10
摘要： The invention relates to methods for the preparation of a pharmaceutical-vesicle formulation comprising steps of: preparing and processing vesicle components and a pharmaceutical agent to entrap the pharmaceutical agent in the vesicle and form a pharmaceutical-vesicle formulation, wherein the pharmaceutical-vesicle formulation is reconstituted in a known quantity of the pharmaceutical agent dissolved in a pharmaceutically-acceptable carrier to provide a biphasic pharmaceutical-vesicle formulation. The invention also relates to the associated pharmaceutical-vesicle formulations, pharmaceutical kits and uses as a medicament, in particular for the prevention or treatment of infection by bacteria such as Burkholderia pseudomallei and Francisella tularensis, and viruses such as Venezuelan Equine Encephalitis Virus (VEEV).
-
公开(公告)号：US20220273834A1
公开(公告)日：2022-09-01
申请号：US17750108
申请日：2022-05-20
申请人： The United States of America, as represented by the Secretary, Department of Health and Human Servic , The University of Strathclyde
摘要： Disclosed herein are methods and devices for the inactivation of pathogens (e.g., bacteria, viruses, etc.) in ex vivo stored blood products, such as plasma and/or platelets, by means of directing visible light radiation from an illuminating device into blood product storage containers in order to achieve effective pathogen inactivation without the presence of an added photosensitising agent in the blood product. An exemplary apparatus includes a control unit that operates a light source that emits light in the wavelength region of about 380-500 nm which is directed onto blood product storage bags at sufficient intensity to penetrate the bag material and the opaque blood product therein in order to inactivate pathogens in the blood product but at dose levels that cause no significant detrimental effects on the blood product.
-
7.发明申请公开(公告)号：US20210316009A1
公开(公告)日：2021-10-14
申请号：US17273059
申请日：2019-09-13
IPC分类号： A61K47/69 , A61K9/127 , A61K47/14 , A61K47/28 , A61K47/24 , A61K47/42 , A61K47/26 , A61K31/65 , A61K31/5383 , A61K31/496 , A61K38/21 , A61K31/513 , A61K31/711 , C07K16/10 , A61P31/14 , A61P31/04 , A61K47/54
摘要： The invention relates to methods for the preparation of a pharmaceutical-vesicle formulation comprising steps of: preparing and processing vesicle components and a pharmaceutical agent to entrap the pharmaceutical agent in the vesicle and form a pharmaceutical-vesicle formulation, wherein the pharmaceutical-vesicle formulation is reconstituted in a known quantity of the pharmaceutical agent dissolved in a pharmaceutically-acceptable carrier to provide a biphasic pharmaceutical-vesicle formulation. The invention also relates to the associated pharmaceutical-vesicle formulations, pharmaceutical kits and uses as a medicament, in particular for the prevention or treatment of infection by bacteria such as Burkholderia pseudomallei and Francisella tularensis, and viruses such as Venezuelan Equine Encephalitis Virus (VEEV).
-
公开(公告)号：US20210278371A1
公开(公告)日：2021-09-09
申请号：US17261336
申请日：2019-07-11
IPC分类号： G01N27/82
摘要： Disclosed herein is a method of detecting a material response. The method includes providing an oscillating primary magnetic field to cause a sample to produce a secondary magnetic field. The method also includes reducing the effect on an atomic magnetometer of components of the primary and secondary magnetic fields in a direction substantially orthogonal to a surface of the sample. The method also includes detecting the secondary magnetic field with the atomic magnetometer to detect the material response.
-
9.发明申请公开(公告)号：US20190070323A1
公开(公告)日：2019-03-07
申请号：US15765424
申请日：2016-09-29
申请人： The US of America, as represented by the Secretary Dept. of Health and Human Servics , The University of Strathclyde
摘要： Disclosed herein are methods and devices for the inactivation of pathogens (e.g., bacteria, viruses, etc.) in ex vivo stored blood products, such as plasma and/or platelets, by means of directing visible light radiation from an illuminating device into blood product storage containers in order to achieve effective pathogen inactivation without the presence of an added photosensitising agent in the blood product. An exemplary apparatus includes a control unit that operates a light source that emits light in the wavelength region of about 380-500 nm which is directed onto blood product storage bags at sufficient intensity to penetrate the bag material and the opaque blood product therein in order to inactivate pathogens in the blood product but at dose levels that cause no significant detrimental effects on the blood product.
-
10.发明授权
公开(公告)号：US5969129A
公开(公告)日：1999-10-19
申请号：US682573
申请日：1996-08-26
申请人： Brian Caddy , Jing Cheng
发明人： Brian Caddy , Jing Cheng
CPC分类号： C12N15/1006
摘要： A process for isolating polynucleotides from aqueous mixtures containing both polynucleotides and polysaccharides is described. The process uses polymer gels containing --B(OH).sub.2 groups, and is useful in purifying deoxyribonucleic acid extracted from plants.
摘要翻译： PCT No.PCT / GB95 / 00150 Sec。 371日期：1996年8月26日 102（e）日期1996年8月26日PCT提交1995年1月26日PCT公布。 公开号WO95 / 20594 日期1995年8月3日描述了从含有多核苷酸和多糖的含水混合物中分离多核苷酸的方法。 该方法使用含有-B（OH）2基团的聚合物凝胶，可用于纯化从植物提取的脱氧核糖核酸。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.025 秒)
